



November 27, 2015

SanBio Co., Ltd.

Speech Delivered by Keita Mori, President of SanBio at
the 2015 World Alliance Forum in San Francisco
~Regenerative Medicine: Let's talk Business!~

The 2015 World Alliance Forum in San Francisco (WAFSF) was held in San Francisco, U.S., for two days from November 11 to 12, 2015 with the theme of "Regenerative Medicine: Let's talk Business!" Keita Mori, President of SanBio Co., Ltd. (hereinafter "the Company") delivered a speech and carried out case discussion concerning the commercialization of regenerative medicine.

The WAFSF is an international conference held for the third year with the theme of regenerative medicine. It is a forum where top researchers, corporate managers and representatives from related organizations from U.S. and Japan gather in San Francisco and hold meetings which aim at discussion on transnational commercialization and industrialization strategies, hence contributing to early realization of such strategies.

During the case discussion, under the moderation of Ms. Susan Solomon, founder and CEO of the New York Stem Cell Foundation, Professor Hideyuki Okano, Dean, Keio University School of Medicine and Keita Mori, President of the Company cited the Company as an example for commercialization, and carried out discussion on the "Road to Commercialization" towards the practicalization of regenerative medicine.

The Company was introduced in the discussion and was highly evaluated for its focus on the construction of the mass production technology of the cell-based medicine for nearly 10 years since the business started in 2001, while continuously supporting the business from the management aspect including fundraising necessary for development, thereby reaching the stage of clinical trials, and even further proceeding to the stage of confirming not only the safety of the Company's cell-based medicine SB623, but also its statistically significant efficacy in Phase 1/2a clinical trials in patients with chronic stroke performed in U.S.

Lastly, according to the discussion with Professor Okano, the importance of the promotion of the commercialization of regenerative medicine as the whole industry was highlighted. It was made clear that the regenerative medicine division does not stand alone as an independent segment. Similarly, cell medicine does not only involve merely the development of cell medicine. Instead, the medicine is expected to be utilized in combination with cell cultivation technology, existing drugs and methods of medical treatment, and, accordingly, further medical advancement can be expected.

Cell-based medicine for regenerative therapy

The proprietary cell-based medicine for regenerative therapy operated by SanBio Co., Ltd. and SanBio, Inc. (hereinafter the "SanBio Group") is expected to have efficacy for regenerating motor, sensory, and cognitive functions by inducing or promoting the body's natural regenerative process for functional deficits caused by diseases or injuries.

About the SanBio Group

The SanBio Group is a regenerative medicine company with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is already in Stage 2 clinical trials for treatment of chronic stroke, and has just begun Stage 2 clinical trials for treatment of traumatic brain injury in October 2015. Based in Tokyo, the Company also has a United States headquarters in the San Francisco Bay Area.

Inquiries about this release
Management Administration, SanBio Co., Ltd.
(TEL.+81-3-6264-3481)